Unknown PHASE3 INTERVENTIONAL 2-arm NCT01061320

Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients

Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures

Sponsor: Thammasat University

Conditions Contrast Induced Nephropathy

Interventions alpha tocopherol placebo

Updated 5 times since 2017 Last updated: Feb 2, 2010 Started: Jan 31, 2010 Primary completion: Oct 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Contrast Induced Nephropathy, this trial is ongoing. The trial is conducted by Thammasat University and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Enrolling By Invitation → Unknown Status
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Thammasat University

Data source: Thammasat University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Khlong Luang, Thailand